ONC
BeOne Medicines Ltd. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26
Figures on this page computed 2026-11-08 12:40 UTC
Last close
377.78USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-02-26
2034.8xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-011946
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
33.6%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-011946
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
5.4%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-011946
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
17.6%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-011946
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
0.25Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-011946
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Price is the furthest below its sector's middle: 0.01 against 0.36 on the market's range.
- Growth76.8%93 of 100, above its sector
- Returns on capital33.6%73 of 100, above its sector
- Margins87.5%76 of 100, above its sector
- Price2034.8x1 of 100, below its sector
- Safety0.2576 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 0 of 4- Profit on each unit of sales5.4%4.1%Ahead
Higher is better here.
- Return on the capital it uses33.6%9.4%Ahead
Higher is better here.
- Sales growth over five years76.9%n/an/a
Higher is better here.
- Debt against equity0.251.21Ahead
Lower is better here.
- Gross margin87.5%26.4%Ahead
Higher is better here.
- Price against earnings2,035xn/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Medline Inc., ONC is behind on 0 of 4 measures.
Against Medline Inc., ONC is behind on 0 of 4 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-26
Profit on each unit of sales5.4%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-011946
- Reported in
- USD
Return on the capital it uses33.6%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-011946
- Reported in
- USD
Sales growth over five years76.8%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-011946
- Reported in
- USD
Debt against equity0.25
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-011946
- Reported in
- USD
Gross margin87.5%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-011946
- Reported in
- USD
Price against earnings2034.8x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-011946
- Reported in
- USD